After 20 years of research, biotech Immunicum, maker of dendritic cell immunotherapeutics, has developed a patented cancer vaccine that works differently than current therapeutic cancer vaccines in that it activates the body's own immune system to attack tumor cells by using mass-produced dendritic cells, and not cells from the patient's own tumor.
This development should make a significant difference across the board in cost, time, difficulty and patient stress.
The vaccine has been tested in pre-clinical trials and the company expects to begin Phase I/II human clinical trials to test safety and efficacy of the vaccine. They will be recruiting at least twelve patients with metastatic renal cancer to trial the vaccine.
Source: Marketwire
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
